Merck & Co., Inc. (SNSE:MRK)

Market Cap	261.61T +6.6%
Revenue (ttm)	58.56T +1.3%
Net Income	16.44T +6.6%
EPS	6,557.61 +8.0%
Shares Out	n/a
PE Ratio	15.91
Forward PE	23.76
Dividend	3,050.72 (2,587.55%)
Ex-Dividend Date	Dec 15, 2025

Volume	n/a
Average Volume	47
Open	n/a
Previous Close	117.90
Day's Range	n/a
52-Week Range	74.48 - 125.13
Beta	0.39
RSI	93.69
Earnings Date	Feb 3, 2026

About Merck & Co.

Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, B...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1891
• Employees: 75,000
• Stock Exchange: Santiago Stock Exchange
• Ticker Symbol: MRK

Financial Performance

In 2025, Merck & Co.'s revenue was $65.01 billion, an increase of 1.31% compared to the previous year's $64.17 billion. Earnings were $18.25 billion, an increase of 6.64%.

Financial numbers in USD